NCT02054182

Brief Summary

The purpose of this study is to determine whether vitamin D supplements given to children aged 1 month to 5 years, hospitalized with acute lower respiratory tract infection will improve symptoms and reduce the duration of hospitalization.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Feb 2014

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2014

Completed
14 days until next milestone

Study Start

First participant enrolled

February 1, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 4, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

February 4, 2014

Status Verified

January 1, 2014

Enrollment Period

9 months

First QC Date

January 18, 2014

Last Update Submit

February 2, 2014

Conditions

Keywords

vitamin D supplementation, pneumonia, bronchiolitis

Outcome Measures

Primary Outcomes (1)

  • Comparison of change from baseline in modified Respiratory Distress Assessment Instrument score at hospital discharge between vitamin D supplement and placebo groups.

    The modified Respiratory Distress Assessment Instrument score, involves the measurement of the child's respiratory rate, assessment of the use of accessory muscles, the child's color, and auscultatory findings; each of these is given a score from 0 to 3. The higher the score the more severe the clinical condition. This scoring system has been validated in a number of scientific studies.

    Participants will be followed for the duration of hospital stay, an expected average of 7 days

Secondary Outcomes (1)

  • Comparison of duration of hospitalization between vitamin D supplementation and placebo groups.

    Participants will be followed for the duration of hospital stay, an expected average of 7 days

Other Outcomes (1)

  • Assessment of correlation between vitamin D levels and modified Respiratory Distress Assessment Instrument score

    On day 1, i.e. date of randomization

Study Arms (2)

Vitamin D

ACTIVE COMPARATOR

Vitamin D 2 500 IU daily from enrolment until hospital discharge

Drug: Vitamin D

Placebo

PLACEBO COMPARATOR

Placebo

Interventions

Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital

Also known as: Cholecalciferol
Vitamin D

Eligibility Criteria

Age1 Month - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • All children age 1month - 5 yrs, admitted in the paediatric unit of Dr George Mukhari Hospital with an acute lower respiratory tract infection i.e. bronchiolitis and/ or pneumonia

You may not qualify if:

  • Children whose caregivers decline participation in the study Children with co-morbid chronic respiratory condition(s) Children who have received vitamin D supplementation in the past 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr George Mukhari Academic Hospital

Pretoria, Gauteng, 0204, South Africa

Location

MeSH Terms

Conditions

PneumoniaBronchiolitis

Interventions

Vitamin DCholecalciferol

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract DiseasesBronchitisBronchial DiseasesLung Diseases, Obstructive

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsCholestenesCholestanesSterolsMembrane LipidsLipids

Study Officials

  • Siyazi Mda, MBChB, PhD

    Univeristy of Limpopo, Medunsa Campus

    STUDY CHAIR

Central Study Contacts

Winter-Rose S Nkosi, MBChB

CONTACT

Nolwandle N Duma, MBChB

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research project supervisor

Study Record Dates

First Submitted

January 18, 2014

First Posted

February 4, 2014

Study Start

February 1, 2014

Primary Completion

November 1, 2014

Study Completion

January 1, 2015

Last Updated

February 4, 2014

Record last verified: 2014-01

Locations